Author pages are created from data sourced from our academic publisher partnerships and public sources.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
BACKGROUND Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal… Expand
Glucocorticoids induce an activated, anti‐inflammatory monocyte subset in mice that resembles myeloid‐derived suppressor cells
- G. Varga, J. Ehrchen, +6 authors C. Sunderkoetter
- Biology, Medicine
- Journal of leukocyte biology
- 1 September 2008
Glucocorticoids (GC) are still the most widely used immunosuppressive agents in clinical medicine. Surprisingly, little is known about the mechanisms of GC action on monocytes, although these cells… Expand
Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study…
- J. Lacour, C. Ulrich, +17 authors R. Szeimies
- Journal of the European Academy of Dermatology…
- 1 December 2015
Unmet needs exist in actinic keratosis (AK) treatment. Daylight photodynamic therapy (DL‐PDT) has shown good efficacy and safety results compared to conventional PDT (c‐PDT) in a recent Phase III… Expand
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician
- R. Gutzmer, J. Becker, +9 authors B. Homey
- Journal der Deutschen Dermatologischen…
- 1 March 2011
Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely develop… Expand
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with… Expand
Immune Suppression via Glucocorticoid-Stimulated Monocytes: A Novel Mechanism To Cope with Inflammation
Glucocorticoids (GCs) are used as first-line therapies for generalized suppression of inflammation (e.g., allergies or autoimmune diseases), but their long-term use is limited by severe side effects.… Expand
Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study
Methods The current placebo-controlled multi-center study was designed to assess the effects of the anti-IL-1s monoclonal antibody canakinumab (CAN) on the clinical signs and symptoms of SchS. We… Expand
Dupilumab treatment improves quality of life in adult patients with moderate‐to‐severe atopic dermatitis: results from a randomized, placebo‐controlled clinical trial
Dupilumab, a human anti‐interleukin‐4 receptor alpha monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate‐to‐severe atopic dermatitis in a randomized,… Expand
Chronic Prurigo of Nodular Type: A Review.
- C. Zeidler, A. Tsianakas, Manuel Pereira, H. Ständer, G. Yosipovitch, S. Ständer
- Acta dermato-venereologica
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules. PN evolves along with… Expand
Induction of an anti-inflammatory human monocyte subtype is a unique property of glucocorticoids, but can be modified by IL-6 and IL-10.
Glucocorticoids (GC) are the most widely used immunosuppressive agents in clinical medicine. Recently we showed that GC enhance survival of human monocytes and induce a specific anti-inflammatory… Expand